Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BouNDless phase 3 trial of continuous subcutaneous ND0612 versus oral immediate-release levodopa/carbidopa in Parkinson's disease with motor fluctuations
MOH_2019-11-17_007469Phase 3Active, not recruiting
- Sponsor
- NeuroDerm Ltd.
- Start
- Oct 2019
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Primary efficacy endpoint. Started Oct 2019; status: active, not recruiting.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2019-11-17_007469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-17_007469.